MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
Cyclacel Pharmaceuticals ROE Ratio 2011-2026 | CYCCP
Annual ROE Ratio Cyclacel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.82 | -515.73 | 3715.82 | -132.99 | -50.69 | -25.39 | -66.94 | -47.72 | -34.32 | -82.61 | -76.15 | -89.39 | -36.23 | -131.61 | -78.17 | -64.28 | -333.28 | -195.65 | -41.49 | -54.26 | -438.16 | -94.94 | -39.78 | 98.52 | 400.85 | -71.23 | 257.74 | -126.13 | 98.98 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3715.82 | -515.73 | 61.67 |
Quarterly ROE Ratio Cyclacel Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -55.78 | 148.89 | -163.22 | 6.63 | 9.27 | -131.11 | -438.93 | -170.1 | -303.65 | -326.74 | -201.51 | -107.73 | -50.53 | -62.59 | -51.36 | -43.45 | -31.16 | -37.94 | -32.4 | -24.2 | -16.96 | -33.22 | -41.68 | -50.91 | -47.24 | -60.78 | -56.67 | -50.25 | -34.5 | -43.03 | -39.54 | -34.55 | -25.72 | -46.36 | -58.61 | -69.86 | -62.72 | -77.1 | -74.23 | -79.54 | -58.23 | -80.86 | -88.66 | -93.34 | -67.26 | -85.12 | -57.17 | -45.98 | -23.53 | -42.39 | -60.24 | -95.06 | -84.06 | -101.73 | -101.08 | -88.9 | -59.41 | -17.67 | -18.22 | -23.53 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 148.89 | -438.93 | -72.73 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-32.54 | - | 1.35 % | $ 17.8 M |  China |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.11 | -4.95 % | $ 197 M |  Israel |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.49 | -5.71 % | $ 175 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-55.55 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
437.8 | - | -13.47 % | $ 169 M | France |
 |
AstraZeneca PLC
AZN
|
21.0 | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
-5.91 | $ 88.43 | -1.3 % | $ 21.4 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
30.52 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-1.17 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
3750.6 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-55.98 | - | -18.52 % | $ 27.3 M | Britain |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 52.04 | -8.62 % | $ 4.68 B |  Schweiz |
 |
Affimed N.V.
AFMD
|
-183.26 | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-948.23 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 28.68 | -4.18 % | $ 1.9 B | USA |
 |
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-44.16 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-7.58 | $ 14.67 | -0.85 % | $ 210 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.17 | 0.32 % | $ 5.22 M | Israel |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-146.95 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 21.81 | -0.66 % | $ 2.77 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-54.92 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |